The Team.

NOVAPEP IS DRIVEN BY A WORLD-CLASS TEAM OF SCIENTISTS AND INDUSTRY LEADERS ADVANCING PEPTIDE-BASED THERAPEUTICS.

SCIENTIFIC ADVISORY BOARD.

Professor, Department of Chemistry, Scripps Research.
Dean Emeritus of Graduate and Postdoctoral Studies, Skaggs Graduate School of Chemical and Biological Science, Scripps Research.
Developer of Methods to Incorporate Unnatural Chemical Groups into Proteins.
Chairman of the Peptide Therapeutics Foundation.

Professor of Laboratory Medicine at Leipzig University.
He is a specialist in internal medicine, endocrinology and laboratory medicine, as well as a diabetologist and clinical chemist.
Focused on protease-dependent signaling in vascular diseases and on diabetes-associated vascular complications and kidney disease.
His group has generated important insights into biased signaling via PARs.

Foundation Professor of Neurology at Macquarie University, Sydney
Clinical neurologist and researcher, whose areas of expertise include Motor Neurone Disease and Parkinson’s Disease.
Authored 106 manuscripts in peer-reviewed journals, in addition to chapters in textbooks on Motor Neurone Disease
Established the MND Research Centre at Macquarie University, which is now the largest integrated basic and clinical research unit in Australia, together with the Neurodegenerative Disease Biobank.

Anchor 1

MANAGEMENT TEAM.

Rob is Managing Partner of Jacanda Capital and Modus Partners.
Previously Director of Strategy at Fairfax Media.
Previously was a strategy consultant with Booz & Co.
He has extensive Board experience of over 20 years with medical research, arts and social enterprise for-purpose organisations.

25 years in corporate advisory services with Citibank and Bank of America.
Co-founded Access Systems, sold to International Gaming Technology Inc.
Co-founded and was CFO of Nuon Therapeutics Inc.
Founder and CEO of Bioatrix Pty Ltd, which was sold to ZZ Biotech LLC, and he is a Director of Prokardia and Kardiomics.

BA, MBA, PhD

Executive Director

Kent Pryor is a Director and Chief Executive Officer of ZZ Biotech.
Previously, he served as Chief Operating Officer of SynthRx, Inc., Associate Director of Drug Development at Kémia, Inc., and Group Leader at Corvas International, Inc.
Dr Pryor received his BA in chemistry magna cum laude from Rice University, a PhD in organic chemistry from the Massachusetts Institute of Technology, and an MBA from the Rady School of Management at the University of California, San Diego.

Anchor 4